ELI LILLY & CO (LLY)

3 Unstoppable Stocks to Buy Right Now

These stocks could be just the ticket for investors seeking strong growth.

Eli Lilly (LLY) Rises Higher Than Market: Key Facts

The latest trading day saw Eli Lilly (LLY) settling at $598.05, representing a +1.66% change from its previous close.

What Eli Lilly’s new obesity drug Zepbound means for GLP-1 weight-loss medication prices

Zepbound has a much lower sticker price than its rival, Novo Nordisk's Wegovy

Eli Lilly raises dividend by 15% to $1.30 (NYSE:LLY)

Eli Lilly (LLY) declares $1.30/share quarterly dividend, 15% increase from prior dividend of $1.13. Forward yield 0.89% Payable March 8; for shareholders of rec

Lilly Announces 15% Dividend Increase, First-Quarter 2024 Dividend

/PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has announced a 15% increase in its quarterly dividend and declared a dividend for...

Could Eli Lilly Beat Novo Nordisk in the Billion-Dollar Weight Loss Market?

These drugs address a rapidly growing market.

Challenging the Magnificent 7: 3 Stocks on the Rise

The S&P 500 is performing well thanks largely to the Magnificent 7. Here are three companies whose stocks could soon join the exclusive club.

Notable Thursday Option Activity: LLY, HES, KRYS

Neuropsychiatric Disorders and Treatment Market Projected to Show Strong Growth: Astrazeneca, AviadoBio, Astellas Pharma

Get an extensive Neuropsychiatric Disorders And Treatment Market analysis of the dominant vendors, their latest products and services, and the competitive landscape of the industry.

Curious about the S&P500 stocks that are gapping on Thursday? Explore the gap up and gap down stocks in the S&P500 index during today's session.

Curious about the S&P500 stocks that are gapping on Thursday? Explore the gap up and gap down stocks in the S&P500 index during today's session.

Eli Lilly breast cancer drug bags label expansion in Canada (NYSE:LLY)

Eli Lilly's breast cancer drug, Verzenio, receives label expansion authorization in Canada, offering treatment options for a broader range of patients at...

Better Large-Cap Growth Fund: Schwab U.S. Large-Cap Growth or Vanguard Growth Index Fund?

Which of these top-performing growth funds is the better buy?

Should You Buy Eli Lilly Stock Now or Wait for a Dip?

Eli Lilly's P/E ratio of more than 100 looks steep, but the company is on the cusp of further huge growth.

Which Stock Is More Likely to Help You Retire as a Millionaire: AbbVie or Eli Lilly?

There's no guarantee that either of these big pharma stocks can help you retire as a millionaire. But one has a clear edge.

Cramer examines Tuesday's market 'mistakes,' points out underappreciated stocks

CNBC's Jim Cramer pointed out investors' mistakes when evaluating mega cap stocks on Tuesday.

Eli Lilly vs. Novo Nordisk: The pros deliver their verdict on the viral weight-loss stocks

Shares in Eli Lilly are up around 60% year-to-date, while Novo Nordisk has gained around 50%. Should investors buy either stock — or both?

Eli Lilly surprised as POINT Biopharma deal is incomplete

Eli Lilly's (LLY) acquisition of radiopharmaceutical company POINT Biopharma (PNT) is facing challenges as investors show lack of interest. Read more here.

Eli Lilly surprised as POINT Biopharma deal is incomplete (NYSE:LLY)

Eli Lilly's (LLY) acquisition of radiopharmaceutical company POINT Biopharma (PNT) is facing challenges as investors show lack of interest. Read more here.

Eli Lilly weight loss drug Zepbound now available at pharmacies as rival Wegovy faces shortages

Eli Lilly's drug serves as an alternative to rival obesity drugs such as Wegovy that are still facing supply issues. 

Lawyers push to consolidate cases linked to weight loss drugs

Law firms are seeking to consolidate lawsuits related to side effects of GLP-1 class of drugs filed against Novo Nordisk (NVO) and Eli Lilly (LLY). Read more here.

Nigo Wants to Stay in the Present, Even If He Is the GOAT

The Human Made and Kenzo designer talks about Virgil Abloh, Bape and what it’s like to work for the world’s biggest luxury company.

Saudis Cut Asia Oil Prices After OPEC+ Deepens Output Curbs

Saudi Arabia cut its official crude oil selling prices to Asia next month amid a continued supply glut, a sign of weakness in markets as OPEC and its allies deepen production cuts in an attempt to avoid a surplus.

Chunk of Norway’s Offshore Gas Finds Risk Going Untapped

A swath of Norway’s offshore gas discoveries risk remaining untapped due to challenges ranging from complex reservoirs to costs of production.

Entain Reaches £615 Million Settlement With UK Over Bribes Probe

Entain Plc. will pay £615 million ($777 million) to resolve a probe with UK prosecutors following an investigation into potential bribery offenses at its former Turkish business.

Eli Lilly’s New Weight-Loss Drug Now on Sale to Rival Hard-to-Find Wegovy

Eli Lilly & Co.’s new weight-loss drug Zepbound is now available at US pharmacies, offering an alternative to rival medications like Novo Nordisk A/S’s Wegovy as supply issues persist.

Eli Lilly and Company’s GLP-1 Weight Loss Drug Is Now Available in the US for as Low as $25

Without any insurance coverage, a monthly dose of Eli Lilly and Company's GLP-1 weight loss drug is priced at $1,060 in the US.

Lilly to Present Final Overall Survival Analysis from the MONARCH 3 Study of Verzenio® (abemaciclib) and Additional Results from Its Breast Cancer Portfolio at the 2023 San Antonio Breast Cancer Symposium

Results from MONARCH 3 show a numerical improvement in overall survival (OS) of 13.1 months for women with HR+, HER2- metastatic breast cancer treated with...

Eli Lilly's obesity drug now available in U.S. pharmacies

The company is making the weight-loss drug accessible to adults through its commercial savings card program, where people who are commercially insured with coverage may be eligible to pay as low as $25 for a 1-month or 3-month prescription. The drug was approved in November, paving the way for a powerful new rival to Novo Nordisk's Wegovy in addressing record obesity rates. Lilly's drug tirzepatide has been available as Mounjaro for type 2 diabetes since 2022 and had increasingly been used "off-label" for weight loss while the obesity approval was pending.

UPDATE 1-Eli Lilly's obesity drug now available in U.S. pharmacies

Eli Lilly's recently approved obesity drug Zepbound is now available in U.S. pharmacies and could be available to some insured customers at $550 per month or half of the list price, the U.S. drugmaker said on Tuesday. The company is making the weight-loss drug accessible to adults through its commercial savings card program, where people who are commercially insured with coverage may be eligible to pay as low as $25 for a 1-month or 3-month prescription. The drug was approved in November, paving the way for a powerful new rival to Novo Nordisk's Wegovy in addressing record obesity rates.

: Eli Lilly’s new obesity drug Zepbound added to major PBM formularies as it hits pharmacy shelves

Eli Lilly & Co. said Tuesday its new obesity drug Zepbound has been added to a major pharmacy benefit manager’s preferred formulary, or list of covered...

Eli Lilly announces U.S. availability of weight loss drug Zepbound (NYSE:LLY)

Eli Lilly's weight loss drug Zepbound (tirzepatide) is now available nationwide, offering potential savings for commercially insured patients.

Zepbound™ (tirzepatide) is Now Available in U.S. Pharmacies for Adults Living with Obesity

/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that Zepbound™ (tirzepatide) injection is now available. Zepbound is indicated for adults...

Bristol Myers gets priority review for urothelial cancer combination therapy (NYSE:BMY)

Bristol Myers Squibb's combination therapy for urothelial carcinoma receives priority review from the FDA, potentially offering a new treatment option in...

Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Friday.

Curious about the top performers within the S&P500 index one hour before the close of the markets on Friday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.

Uncovering Noteworthy Technical Analysis Findings for ELI LILLY & CO (NYSE:LLY).

Promising Signs: ELI LILLY & CO Setting the Stage for a Breakout.